EUCTR2010-019645-25-ITActive, not recruitingNot Applicable
A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of FBS0701 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. - ND
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- FERROKIN BIOSCIENCES INC.
- Enrollment
- 40
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Willing and able to sign the approved informed consent. 2. Age: 18-60 years old at Screening 3. Transfusional iron overload due to: hereditary anemias such as sickle cell disease, ß-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and other forms of bone marrow failure. Patients must also: a. Be transfusion-dependent (8 or more transfusions annually) and b. Require chronic treatment with deferoxamine, deferasirox, and/or deferiprone. 4. Willing to discontinue all existing iron chelation therapies for a minimum period of two to five days prior to first dose of FBS0701, the 24 week duration of the study and 1 week after last dose for a total of approximately 26 weeks. 5. Serum ferritin > 500 ng/mL at Screening. 6. Baseline (Day -14 to Day -7) liver iron concentration (LIC) between =3.5 and <30 mg iron per g (equivalent dry weight, liver) determined by FerriScan MRI. 7. Baseline (Day -14 to Day -7) cardiac MRI T2* =10 milliseconds. 8. Mean of the previous three pre-transfusion hemoglobin concentrations = 7.5 g/dL. 9. Agrees to use an approved method of contraception from Screening and until 28 days after the last administration of the study drug. Agreed methods of contraception may include: condom; use of birth control pills, patches, implants or injections, diaphragm with vaginal spermicide, intrauterine device (IUD) and/or surgical sterilization (vasectomy or tubal ligation at least six months prior to dosing). Patients practicing abstinence must agree to use an approved method of contraception should they become sexually active during the study. A monthly pregnancy test will be performed on all female patients of child-bearing potential during the Screening and study period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •1.As a result of medical review, physical examination or Screening investigations, the Principal Investigator considers the patient unfit for the study. 2.Non-elective hospitalization within the 30 days prior to Baseline testing. (Patients with sickle cell anemia who are admitted to the hospital for management of sickle crisis pain whose uncomplicated hospital course was four days or less and who, 14 days prior to Baseline testing, have returned to their previous health status are acceptable.) 3.Evidence of clinically relevant oral, cardiovascular, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric, immunologic, bone marrow or skin disorder as determined by the Investigator. 4.Evidence of significant renal insufficiency; e.g., serum creatinine above the upper limit of normal, proteinuria greater than 2 gm per day or calculated creatinine clearance of less than 60 mL/minute. 5.Cardiac left ventricular ejection fraction: a.Outside the locally determined normal range in the 12 months prior to Screening by echocardiography or MRI and b.<55% at Baseline testing by MRI 6.Known sensitivity to magnesium stearate, croscarmellose sodium or FBS0701 7.Platelet count below 150,000/?L and/or absolute neutrophil count less than 1500/mm3 at Screening 8.Alkaline phosphatase, AST or ALT a.>5 times the local upper limit of normal at any time in the previous 12 months or b.>3 times the upper limit of normal at Screening 9.Use of any investigational agent within the 30 days prior to the Baseline testing.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Treatment of chronic iron overload with a chelation therapy (FBS0701)Patients with transfusional iron overload, with the following primary diagnosis:hereditary anemia (such as sickle cell disease),ß-thalassemia and Diamond Blackfan anemiaEUCTR2011-005675-16-ITFERROKIN BIOSCIENCES INC.50
Active, not recruiting
Phase 1
A 24 week trial to study the safety and tolerability of SSP-004184 in the treatment of patients with longterm iron overload who need iron chelation therapy, with the option of 72 weeks further dosing.EUCTR2010-019645-25-GBShire Development LLC50
Completed
Phase 2
Assessing the safety, tolerability, and pharmacodynamics of FBS0701 in the treatment of chronic iron overload requiring chelation therapyISRCTN17052121FerroKin BioSciences Inc. (USA)40
Active, not recruiting
Phase 1
Revaccination of healthy non-pregnantwomen with a second dose of a vaccine to asess its safety and the protection it gives from blood poisoning caused by a bacteriumHealthy person immune response to a second dose of Group B Streptococcuspolysaccharide capsule antigensMedDRA version: 18.1Level: PTClassification code 10053588Term: Group B streptococcus neonatal sepsisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003094-15-BEGlaxoSmithKline Biologicals S.A.
Active, not recruiting
Phase 1
Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with SCCHPatients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck (SCCHN)MedDRA version: 18.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003717-29-FRAstraZeneca AB240